scholarly journals A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions

Cancer ◽  
2008 ◽  
Vol 112 (3) ◽  
pp. 650-658 ◽  
Author(s):  
Michael T. Milano ◽  
Alan W. Katz ◽  
Ann G. Muhs ◽  
Abraham Philip ◽  
Daniel J. Buchholz ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Pilot Study ◽  
Stereotactic Body Radiation Therapy ◽  
Curative Intent ◽  
Stereotactic Body Radiation ◽  
Prospective Pilot Study

Stereotactic Body Radiation and Other Ablative Therapies

2018 ◽  
Author(s):  
Praveen Sridhar ◽  
Hiran C Fernando
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Thermal Ablation ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Curative Intent ◽  
Stereotactic Body Radiation ◽  
Percutaneous Thermal Ablation ◽  
Stage Lung Cancer

Lung cancer is the leading cause of cancer death in both men and women. This is related to the high prevalence and high mortality particularly when presenting at an advanced stage. Surgical resection remains the standard curative therapy for early-stage lung cancer. However, many patients are not able to tolerate resection secondary to poor respiratory reserve and other comorbid diseases. Stereotactic body radiation therapy (SBRT) and percutaneous thermal ablation are minimally invasive techniques that have been used to treat other solid tumors with curative intent. Over the past decade, there has been an expansion in the roles of both SBRT and thermal ablation in the treatment of early-stage lung tumors. The encouraging results from several studies have led to the incorporation of these therapies, particularly SBRT, as the standard of care for curative-intent treatment of patients with medically inoperable early-stage lung cancer. This chapter presents an overview of the approach to patient selection as well as provides a review of the current evidence for SBRT, percutaneous thermal ablation, and bronchoscopic ablation for early-stage nonsmall cell lung cancers. This review contains 3 figures, 4 tables, and 28 references Key Words: stereotactic body radiation therapy, percutaneous thermal ablation, cryoablation, microwave ablation, endoscopic ablation, bronchoscopic ablation, radiofrequency ablation, early stage NSCLC therapy

A pilot study of AMP-224—a PD-1 inhibitor—in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. TPS788-TPS788 ◽  
Author(s):  
Austin G. Duffy ◽  
Oxana V. Makarova-Rusher ◽  
Suzanne Fioravanti ◽  
Melissa Walker ◽  
Aradhana Venkatesan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Radiation Therapy ◽  
Pilot Study ◽  
Metastatic Colorectal Cancer ◽  
Tumor Immunity ◽  
Stereotactic Body Radiation Therapy ◽  
Cytotoxic T Cells ◽  
Stereotactic Body Radiation ◽  
Activated T Cell

TPS788 Background: AMP-224, a B7-DC Fc fusion protein, binds to PD-1, an inhibitory receptor that is present on the cell surface of exhausted, activated, effector, and memory T cells. AMP-224 has a unique mechanism of action in that it binds specifically to PD-1HI T cells (chronically stimulated / exhausted T cells) but not to PD-1LOcells which represent the normal activated T cell population. Several preclinical studies have documented an increase in peripheral antitumor immunity following radiation, a phenomenon known as the “abscopal effect”. Tumor PD-L1 expression has also been shown to be induced by radiation, which can suppress the anti-tumor immune response. Inhibition of PD-1/PDL-1 axis has been shown to improve anti-tumor immunity by blocking the tumor-mediated suppression of cytotoxic T cells. The aim of the study is to evaluate whether the anti-tumor immunity of anti-PD1 therapy (with AMP-224) can be enhanced by radiation therapy. Methods: Patients with histologically confirmed metastatic colorectal cancer to liver are being enrolled to this pilot study. The objectives are to determine the safety, tolerability and feasibility of AMP-224 in combination with stereotactic body radiation therapy (SBRT) to metastatic hepatic metastasis in patients with advanced colorectal cancer. Select eligibility are as follows: at least 1 measurable metastatic hepatic lesion by RECIST 1.1 criteria and amenable to SBRT. Patient must have progressed on or been intolerant of at least one prior oxaliplatin- and/or irinotecan-containing regimen and have metastatic lesions that are not amenable to curative resection; ECOG ≤ 1; Life expectancy of greater than 3 months. Acceptable organ and bone marrow function. No active or prior documented autoimmune or inflammatory disorders. Clinical trial information: awaited.

Sign in / Sign up

Export Citation Format

Share Document